Introduction {#S1}
============

Tinnitus is the second most frequent symptom in vestibular schwannoma (VS) patients ([@B1]). Approximately 65--75% of the VS patients complaint about tinnitus ([@B2], [@B3]), in 10% of the patient it is even the presenting symptom ([@B1]). Furthermore, tinnitus is a major factor impairing the VS patients' quality of life ([@B4]--[@B6]).

The current pathophysiological concept of non-VS tinnitus (e.g., idiopathic tinnitus, tinnitus after auditory or baric trauma) hypothesizes a maladaptive neuroplasticity on a cochlear, brain stem, and/or cortical level as a consequence of (hidden) hearing impairment. These neuroplastic changes are supposed to cause a neuronal hyperexcitability for the residual auditory input resulting in the subjective misperception ([@B7]--[@B10]). Hence, hearing impairment has been shown to be the strongest predictor for non-VS tinnitus ([@B7]--[@B11]). In contrast, the pathophysiology of VS-associated tinnitus remains unclear. There are several potential mechanisms of tinnitus generation suggested in the literature ([@B12]): (i) ephaptic coupling of cochlear nerve fibers by compression ([@B13]), (ii) cochlear dysfunction by ischemia or by biochemical degradation ([@B14]), (iii) efferent system dysfunction following compression of the efferent fibers in the inferior vestibular nerve ([@B15]), and (iv) cortical reorganization following hearing loss ([@B9]). Most studies trying to understand the pathophysiology of VS-associated tinnitus by evaluating its clinical predictors have shown an inverse relationship between tumor size and preoperative tinnitus ([@B3], [@B12], [@B16]--[@B19]). In contrast to non-VS tinnitus, only few studies have shown an association between preoperative hearing impairment and tinnitus ([@B3], [@B12], [@B17]). In a series of 1,000 patients, the rate of tinnitus was higher in hearing than in deaf patients (74 and 46%, respectively) ([@B3]). Another study indicates patients with tinnitus to have better hearing than patients without tinnitus, although not reaching statistical significance ([@B17]). Similar data are provided by a study in 941 VS patients showing that patients without hearing loss are less likely to experience tinnitus ([@B12]). However, no study was able to prove a correlation between tinnitus and hearing impairment, as measured by audiometric thresholds. In contrast, a correlation between patient's age and VS-associated tinnitus was observed ([@B12], [@B17]). Finally, several other studies could not establish any predictors of VS-associated tinnitus ([@B4], [@B5], [@B20]).

We hypothesize, that in case VS-associated tinnitus is based on similar pathophysiological principles as non-VS tinnitus, a distinct relationship between tinnitus and hearing impairment is expected. Reviewing literature several possible explanations for the inconclusive evidence have been identified. Most studies have applied bivariate statistics that might have obscured the factual relationship between hearing impairment and VS-associated tinnitus. First, there is a known interaction between preoperative hearing impairment and VS size ([@B21]). Second, a bivariate analysis assumes a linear correlation; however, the available data imply a more complex relationship between tinnitus, tumor size, and hearing impairment ([@B12]). Hence, a multivariate analysis is more appropriate to disentangle clinical predictors of VS-associated tinnitus. However, multivariate statistics necessitates large patient numbers that were available only for few studies ([@B3], [@B12], [@B17], [@B18]).

The objective of this study was to determine clinical predictors (i.e., patient age, gender, tumor size, and hearing impairment) of VS-associated tinnitus in a large neurosurgical patient cohort using a multivariate logistic regression.

Materials and Methods {#S2}
=====================

Patients {#S2-1}
--------

All patients enrolled in this retrospective cross-sectional study underwent a neurosurgical removal of a unilateral sporadic VS in the Neurosurgical Department of the University of Tuebingen between January 2008 and January 2015. First, we identified all patients undergoing surgical treatment for intracranial neoplasms of the cranial nerves in this time period (*n* = 702) based on their ICD-10 code (ICD-10: D33.3). 21 patients were excluded due to the histological findings other than VS. Second, we excluded all patients with neurofibromatosis II (ICD-10: Q85.0) and bilateral VS (*n* = 61), patients with relapse or postradiation surgery (*n* = 40) and known contralateral hearing loss \[Gardner and Robertson (GR) grading \>2, *n* = 8\] resulting in 572 patients for bivariate analysis (Table [1](#T1){ref-type="table"}). However, pure-tone audiograms were missing in 94 patients. Hence, only 478 complete datasets were included to the final multivariate statistical analysis (Table [2](#T2){ref-type="table"}). Preoperatively, all patients received a clinical evaluation of VS-associated symptoms, a hearing evaluation by an ear--nose--throat specialist (pure-tone audiogram and speech discrimination) and a magnetic resonance imaging of the brain. Patients' characteristics are summarized in Table [1](#T1){ref-type="table"}. This study was carried out in accordance with the recommendations of the ethics committee of the Eberhardt Karls University Tuebingen for retrospective studies of data collected as part of routine diagnosis and treatment.

###### 

Patient cohort.

  --------------------------------------------------------------------------------------------------------------
                                          TN−                TN+                
  --------------------------------------- ------------------ ------------------ --------------------------------
  **Age (years)**                         38.5% (184/478)\   61.5% (294/478)\   *t*~(476)~ = 0.54; *p* = 0.587
                                          48.4 ± 14.1        47.8 ± 11.7        

                                                                                

  **Gender**                                                                    

  f                                       63.6% (117/184)    47.6% (140/294)    *X*~(1)~ = 11.61; *p* = 0.001

  m                                       36.4% (67/184)     52.4% (154/294)    

                                                                                

  **Tumor side**                                                                

  Left                                    45.1% (83/184)     466% (137/294)     *X*~(1)~ = 0.10; *p* = 0.750

  Right                                   549% (101/184)     53.4% (157/294)    

                                                                                

  **Tumor size (Hannover)**                                                     

  T1                                      3.8% (7/184)       6.8% (20/294)      *X*~(3)~ = 10.18; *p* = 0.017

  T2                                      19.6% (36/184)     21.8% (64/294)     

  T3                                      36.4% (67/184)     44.6% (131/294)    

  T4                                      40.2% (74/184)     26.9% (79/294)     

                                                                                

  **Hearing loss (Gardner--Robertson)**                                         

  GR1                                     47.8% (88/184)     43.2% (127/294)    *X*~(4)~ = 28.81; *p* \< 0.001

  GR2                                     22.3% (41/184)     25.2% (74/294)     

  GR3                                     14.7% (27/184)     20.7% (61/294)     

  GR4                                     1.6% (3/184)       7.8% (23/294)      

  GR5                                     13.6% (25/184)     3.1% (9/294)       
  --------------------------------------------------------------------------------------------------------------

###### 

Logistic regression predicting likelihood of tinnitus based on tumor size, tumor side, hearing impairment, and gender.

             *B*      SE      Wald     Df   *p*     Odds ratio (OR)   95% Confidence interval for OR   
  ---------- -------- ------- -------- ---- ------- ----------------- -------------------------------- --------
  GR                          24.496   4    0.000                                                      
  GR2        0.345    0.252   1.877    1    0.171   1.412             0.862                            2.312
  GR3        0.643    0.289   4.969    1    0.026   1.903             1.081                            3.350
  GR4        2.105    0.652   10.418   1    0.001   8.211             2.286                            29.489
  GR5        −1.026   0.431   5.663    1    0.017   0.359             0.154                            0.835
  SIZE                        12.093   3    0.007                                                      
  T2         −0.455   0.504   0.815    1    0.367   0.634             0.236                            1.704
  T3         −0.370   0.483   0.586    1    0.444   0.691             0.268                            1.781
  T4         −1.113   0.492   5.109    1    0.024   0.329             0.125                            .863
  AGE        −0.006   0.008   0.613    1    0.434   0.994             0.978                            1.010
  GENDER     0.618    0.202   9.359    1    0.002   1.854             1.248                            2.754
  SIDE       −0.074   0.203   0.133    1    0.715   0.929             0.624                            1.382
  Constant   0.947    0.605   2.448    1    0.118   2.579                                              

*Tumor size is T2, T3, and T4 compared to T1; hearing impairment is GR2, GR3, GR4, and GR5 compared to T1; and gender is for males compared to females*.

Clinical Evaluation {#S2-2}
-------------------

All patients underwent a thorough clinical evaluation of VS-associated symptoms (i.e., hearing impairment, tinnitus, dizziness, balance problems, facial palsy, facial dysesthesia, swallowing difficulties, headache, nausea, and vomiting) by a semi-structured interview by experienced neurosurgeons. Finally, the presence of ipsilateral tinnitus symptoms was dichotomized for statistical analysis (0: no tinnitus, TN−; 1: tinnitus present, TN+).

Grading of the Hearing Loss {#S2-3}
---------------------------

Hearing impairment was classified according to the GR scale ([@B22]). As most of the hearing tests were performed outside of our center, details of the used speech discrimination tests were missing (i.e., word lists, masking, etc.). Hence, grading was based exclusively on the results of the pure-tone audiometry (PTA) resulting in five classes: GR 1 (good, PTA 0--30 dB), GR 2 (serviceable, PTA 31--50 dB), GR 3 (non-serviceable, PTA 51--90 dB), GR 4 (poor, PTA 51--90 dB), and GR 5 (deaf, PTA 0 dB). To show the relationship between the absolute hearing impairment and the occurrence of tinnitus, we have reanalyzed the data with narrow binning of the PTA: (1) 0--10 dB, (2) 11--20 dB, (3) 21--30 dB, (4) 31--40 dB, (5) 41--50 dB, (6) 51--60 dB, (7) 61--70 dB, (8) 71--80 dB, (9) 81--90 dB, (10) 91--100 dB, and (11) \>100 dB ([@B23]).

Tumor Size Classification {#S2-4}
-------------------------

In all patients, a preoperative magnetic resonance image of brain with gadolinium contrast was available, and tumor extent was graded according to Hannover classification ([@B3]). VS were classified into four classes: T1 (purely intrameatal), T2 (intra- and extrameatal), T3 (filling the cerebellopontine cistern), and T4 (compressing the brain stem).

Statistics {#S2-5}
----------

All statistical tests were performed using SPSS (IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY, USA: IBM Corp.). Group differences in distribution of clinical attributes such as gender, age, tumor side, tumor size, and preoperative hearing impairment were evaluated by Student's *t*-test or chi-square test. Binary logistic regression analysis was used to determine the predictive value of gender (GENDER), age (AGE), tumor side (SIDE), tumor size (SIZE), and preoperative hearing impairment (GR) for the occurrence of tinnitus (0: TN+ and 1: TN−). Predictive values of the included variable are provided by their odds ratios (OR) together with the 95% confidence interval (95% CI). Data are shown as mean ± standard deviation (SD). Statistical significance was considered with *p* \< 0.05 for each statistical test.

Results {#S3}
=======

The bivariate analysis showed significant differences between TN+ and TN− patients for gender, tumor size, and hearing impairment. There was a preponderance of male gender, larger tumors (in particular T3), and better hearing function (GR1--GR4) in the TM+ group (Figure [1](#F1){ref-type="fig"}). There were no significant group differences for age and tumor side (Table [1](#T1){ref-type="table"}). To ascertain the effects of gender (GENDER), age (AGE), tumor side (SIDE), tumor size (SIZE), and preoperative hearing impairment (GR) on the likelihood of preoperative VS-associated tinnitus, a binomial logistic regression was performed. The logistic regression model was statistically significant \[χ^2^(10) = 52.50, *p* \< 0.0001\]. Of the five predictor variables GR, SIZE, and GENDER were statistically significant (Table [2](#T2){ref-type="table"}). The binary logistic regression analysis identified male gender (*p* = 0.002) and hearing impairment GR3 (*p* = 0.026) and GR4 (*p* = 0.001) as positive predictors. Patients with male gender \[OR 1.90 (1.25--2.75)\] and higher hearing impairment showed higher odds to exhibit a preoperative tinnitus \[GR3: OR 1.90 (1.08--3.35) and GR4: OR 8.21 (2.29--29.50)\] than patients with no preoperative hearing impairment (GR1), with severe hearing impairment (GR4) being the strongest predictor of tinnitus. In contrast, large T4 tumors (*p* = 0.024) and complete hearing loss GR5 (*p* = 0.017) were identified as negative predictors. Patients with large T4 tumors \[OR 0.33 (0.13--0.86)\] and complete hearing loss GR5 \[OR 0.36 (0.15--0.84)\] were less likely to develop a tinnitus. However, 43.2% (127/294) of the patients with good clinical hearing suffer from tinnitus. In contrast, 26.5% (9/34) of patients with complete hearing loss suffered from tinnitus.

![Distribution of patients with (TN+) and without (TN−) preoperative vestibular schwannoma-associated tinnitus depending on **(A)** tumor side, **(B)** tumor size (Hannover classification, T1--T4), **(C)** preoperative hearing impairment (Gardner and Robertson scale, GR1--GR5), and **(D)** gender.](fneur-08-00378-g001){#F1}

To proof the increased risk of developing tinnitus depending on the hearing impairment, we reanalyzed the data with narrow binning of the PTA values. A binomial logistic regression was performed to show the predictive value of the PTA for the presence of tinnitus. The logistic regression model was statistically significant \[χ^2^(10) = 32.17, *p* \< 0.0001\] with PTA being a significant predictor of tinnitus (*p* = 0.002). Patients with PTA \>100 dB were less likely to present a preoperative tinnitus than other patients (Table [3](#T3){ref-type="table"}). However, for patients with residual hearing, there was positive relationship between hearing impairment and the risk of tinnitus occurrence (Figure [2](#F2){ref-type="fig"}).

###### 

Logistic regression predicting likelihood of tinnitus based on pure-tone audiometry (PTA).

               *B*      SE      Wald     Df   *p*     Odds ratio (OR)   95% Confidence interval for OR   
  ------------ -------- ------- -------- ---- ------- ----------------- -------------------------------- --------
  PTA                           27.438   10   0.002                                                      
  0--10 dB     1.452    0.527   7.587    1    0.006   4.274             1.520                            12.012
  11--20 dB    1.419    0.440   10.373   1    0.001   4.131             1.742                            9.794
  21--30 dB    1.233    0.452   7.440    1    0.006   3.431             1.415                            8.322
  31--40 dB    2.039    0.481   17.974   1    0.000   7.680             2.993                            19.708
  41--50 dB    1.457    0.475   9.394    1    0.002   4.293             1.691                            10.899
  51--60 dB    1.715    0.564   9.253    1    0.002   5.556             1.840                            16.771
  61--70 dB    1.532    0.533   8.256    1    0.004   4.630             1.628                            13.168
  71--80 dB    1.715    0.672   6.518    1    0.011   5.556             1.489                            20.722
  81--90 dB    2.200    0.691   10.128   1    0.001   9.028             2.328                            35.003
  91--100 dB   2.771    0.667   17.269   1    0.000   15.972            4.323                            59.010
  Constant     −1.022   0.389   6.907    1    0.009   0.360                                              

*ORs are provided compared to PTA \>100 dB*.

![Graph is showing the odds ratios (ORs) provided by the logistic regression for the occurrence of tinnitus when compared to patients with pure-tone audiometry (PTA) \>100 dB. Patients with PTA \>100 dB showed the smallest risk for tinnitus. In patients with residual function, however, there was an increase of the ORs with increasing hearing impairment.](fneur-08-00378-g002){#F2}

Discussion {#S4}
==========

This study evaluated the clinical predictors of preoperative tinnitus in unilateral sporadic VS patients indicating male gender and hearing impairment as positive predictors of tinnitus. In contrast, large tumors and complete hearing loss were disentangled as negative predictors in our patient cohort.

Relationship between VS-Associated Tinnitus and Tumor Size {#S4-1}
----------------------------------------------------------

So far, most studies evaluating the clinical predictors of VS-associated tinnitus have shown an inverse relationship between tumor size and tinnitus ([@B3], [@B12], [@B16]--[@B19]). In line, our data show no predictive value of tumor size except the fact that patients with extreme large tumors (i.e., Hannover classification T4) are less likely to experience a tinnitus. Most of the available studies include VS patients treated mainly by the so-called translabyrinthine approach covering rather smaller VS ([@B5], [@B12], [@B16], [@B20], [@B24]) In contrast, due to the retrosigmoidal approach used in our department, this study is covering a high proportion of extreme large tumors (i.e., Hannover classification T4) ([@B3], [@B4], [@B17], [@B24], [@B25]). This fact might have contributed to our findings on the relation between tumor size and tinnitus. A detailed look at the statistics indicates that patients with small tumors (i.e., Hannover classification T1) have the largest risk of preoperative tinnitus in comparison to T2--T4 tumors, however, reaching statistical significance only in contrast to T4 tumors. To our opinion, the most likely explanation for this finding is that tinnitus might lead these patients to an early consultation with physicians, resulting in earlier detection of small tumors ([@B3], [@B17]). On the other, as T4 tumors are reaching the brain stem an interaction between tumor and the cochlear nucleus by compression cannot be excluded.

Impact of Age, Tumor Side, and Gender on VS-Associated Tinnitus {#S4-2}
---------------------------------------------------------------

In this study, no correlation between patient's age or tumor side and VS-associated tinnitus was observed. In contrast, Kameda and colleagues found that patients suffering from VS-associated tinnitus are younger than patients without VS-associated tinnitus ([@B17]). Contradictory, Baguley and colleagues have shown a positive correlation between age and tinnitus severity, i.e., greater age being associated with greater tinnitus severity ([@B12]). Notably, in our analysis, male gender seems to be a positive predictor of VS-associated tinnitus. While there are some studies claiming a male preponderance in non-VS tinnitus ([@B26], [@B27]), most studies indicate female patients to be more affected ([@B28]--[@B30]). These gender differences could be related to different stress coping or anxiety sensitivity ([@B30], [@B31]). However, it remains unclear, how these findings refer to VS-associated tinnitus, when the tinnitus is superimposed by a tumor diagnosis and the need to surgical treatment. In such situation, men might exhaust their personal coping resources faster than women. Nevertheless, the relation between tinnitus and gender is still ambiguous. However, most studies demonstrate no association between tinnitus, gender, age, or VS tumor side ([@B4], [@B5], [@B18], [@B20]).

Relationship between VS-Associated Tinnitus and Hearing Impairment {#S4-3}
------------------------------------------------------------------

Applying a multivariate analysis, this study is the first one to establish a significant, however, non-linear relationship between hearing impairment and VS-associated tinnitus. Our data show that higher preoperative hearing impairment is increasing the risk of developing a tinnitus while complete deafness, in turn, is reducing the risk. However, our data also show that 60% of the patients with good clinical hearing suffer from tinnitus. On the other hand, approximately 23% of the patients with complete hearing loss are suffering from preoperative tinnitus. For the first time, these findings indicate a non-linear relationship between hearing impairment and VS-associated tinnitus. To our opinion, this finding can be partially attributed to our retrosigmoidal approach, which resulted in a patient cohort with less preoperative hearing impairment ([@B3], [@B4], [@B17]) than other studies applying mainly the translabyrinthine approach ([@B5], [@B12], [@B16], [@B20], [@B24]). Our results are in good accordance with literature about non-VS tinnitus indicating hearing loss as main risk factor ([@B7]--[@B10]). Nevertheless, it is well known from non-VS tinnitus that clinical hearing impairment, as measured by the audiometry, is no necessary to develop tinnitus ([@B11], [@B32], [@B33]). This finding could be explained by the fact that some forms of auditory deafferentation are not discovered by audiometry, e.g., patients with tinnitus who have normal hearing thresholds frequently are shown to have cochlear dead regions or outer hair cell damage compared with controls ([@B10], [@B32]). On the other hand, the sensitivity of the PTA might be insufficient to detect subtle (or hidden) hearing impairment ([@B11], [@B33]). In patients with non-VS tinnitus and normal hearing, Schaette and McAlpine have shown an association between tinnitus and a wave I amplitude reduction of the acoustic-evoked potentials, which is generated by primary auditory nerve fibers. This finding is supposed to be a physiological marker of reduced neural output from the cochlea. At the same time, however, the more centrally generated wave V presented a normal amplitude. These findings were interpreted as a renormalization of neuronal response magnitude to the reduced afferent input within the brainstem compensating the hearing loss ([@B11]). Our data show a significant increase of tinnitus occurrence in patients with non-serviceable hearing (GR3 and GR4) indicating that residual, possibly non-functional, activity of the acoustic nerve promotes the occurrence of tinnitus ([@B7]--[@B10]). In line, there is evidence that cochlear nerve preservation with non-functional hearing seems to predict a new-onset tinnitus after surgical VS removal ([@B18], [@B34]). Finally, although hearing impairment could be the initial source of tinnitus, the subsequent cascade of maladaptive neuroplasticity in the central auditory system is likely perpetuate the tinnitus even without any residual input from the ear. This explains the occurrence of VS-associated tinnitus in patients with complete deafness and the fact that tinnitus is persisting even when afferent input from the ear is eradicated by cutting of the auditory nerve loss ([@B35], [@B36]). In contrast, re-installing functional hearing by cochlear implants has been shown to reduce tinnitus ([@B37], [@B38]).

Limitations of the Study {#S4-4}
------------------------

A major limitation of the study is the dichotomization of the patients' tinnitus complaints. Unfortunately, there are no systematic data on the tinnitus severity available loosing important information about the exact relation between tinnitus intensity and hearing impairment. Indeed, there are few studies using dedicated scores in VS-associated tinnitus. For example, Baguley and colleagues have shown a positive correlation between age and tinnitus severity. However, there was no significant association to hearing impairment ([@B12]).

Conclusion {#S5}
==========

This study proves hearing impairment as the most important predictor of VS-associated tinnitus. This finding suggests similar pathophysiological mechanisms for VS-associated and non-VS tinnitus. A better understanding of the VS-associated tinnitus could pave the way for new therapeutic approaches (e.g., non-invasive neurostimulation).
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